PharmAbcine Inc. (KOSDAQ: 208340) announced today that the abstract summarizing interim data on its phase Ib trial of olinvacimab in combination with Merck’s anti-PD-1 antibody Keytruda® for recurrent glioblastoma multiforme (rGBM) patients has been accepted at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting.
PharmAbcine Inc. (KOSDAQ: 208340) announced today that the abstract summarizing interim data on its phase Ib trial of olinvacimab in combination with Merck’s anti-PD-1 antibody Keytruda® for recurrent glioblastoma multiforme (rGBM) patients has been accepted at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting.
Phase Ib study is to evaluate the safety of the combination therapy of two agents for rGBM patients and to explore appropriate clinical dose levels of the two agents as in a combination regimen. During the study, 200 mg of Keytruda® was administered to patients every three weeks while 12 or 16 mg/kg of olinvaciamb was administered on a weekly basis. From the phase Ib study, there was no DLT (dose limiting toxicity) observed, and among 9 patients, 4 patients had SD (stable disease) and 5 patients experienced disease progression (PD).
rGBM is a rare tumor and there are only a few treatment options available to date. It is known to have the worst prognosis among any other types of cancers/tumors and the life expectancy of rGBM patients is less than 4 months upon diagnosis. There have been multiple clinical trials using immuno-oncology drugs to treat rGBM but the promising results have not been reported yet.
Previously Olinvacimab from its phase IIa clinical study in rGBM patients ascertained its significant improvement of brain edema and shrinkage of tumor. Now its use is being investigated in a phase II study for Avastin-refractory rGBM patients in US and Australia.
An ASCO annual meeting is a global conference, annually accommodating 40,000 people from 76 different countries.
About PharmAbcine Inc.
PharmAbcine is a clinical-stage biotech company focusing on the development of fully human antibody therapeutics to treat neovascular disorders and tumors by targeting molecules involved in angiogenesis and immune checkpoints, which are responsible for hindrance in immune response to tumors. Our innovative discovery technology coupled with dedicated R&D staff have enabled us to provide superlative therapeutic antibodies for a wide array of indications in oncology, immuno-oncology, ophthalmology, and renal pathology.
PharmAbcine’s HuPhage library and innovative selection system are priceless proprietary assets that can generate antibodies with greater diversity than 10^11.
PharmAbcine’s advanced 3G expression system accommodates high levels of antibody production with high reproducibility. With our highly advanced technology platforms, we provide high-quality antibody generation services.
PharmAbcine’s advanced evaluation platforms can facilitate the pipeline development by assessing its anti-tumor effects with greater precision and accuracy. Through the collaboration with Samsun Medical Centre, We have more than 300 patients-derived cancer stem cell libraries and a PDX (patient-derived xenograft) animal model system to evaluate internal pipeline development.
Additional information about PharmAbcine can be found on our website at http://www.pharmabcine.com
Contacts
Yohan Jung
82-42-863-2017
yohan.jung@pharmabcine.com
